负向免疫检查点分子在自身免疫性眼病中作用的研究进展  

Current research status of negative immune checkpoint factors in autoimmune eye diseases

作　　者：冯慧 王红[1] Feng Hui;Wang Hong(Beijing Ophthalmology&Visual Science Key Laboratory,Beijing Institute of Ophthalmology,Beijing Tongren Eye Center,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China)

机构地区：[1]首都医科大学附属北京同仁医院北京同仁医院眼科中心北京市眼科学与视觉科学重点实验室,北京100730

出　　处：《中华眼底病杂志》2024年第5期402-408,共7页Chinese Journal of Ocular Fundus Diseases

基　　金：北京市自然科学基金(7212016)。

摘　　要：自身免疫性眼病是一种炎症性眼病,其发病机制涉及自身免疫反应,包括自身免疫性葡萄膜炎、甲状腺相关性眼病、干燥综合征相关性干眼症等多种类型。近些年来,免疫检查点分子已经在诱导移植耐受、肿瘤免疫逃避以及防止自身免疫性疾病方面实现了突破性进展。负向免疫检查点通过抑制T细胞的增殖,降低炎症细胞因子水平,最终调节自身免疫平衡从而有效地控制疾病的发展。因此,未来有望将负向免疫检查点分子作为一种新的治疗靶点,并且通过联合靶向负向免疫检查点药物的联合治疗有望成为提高治疗自身免疫性疾病效果的重要方向。Autoimmune ocular diseases are a type of inflammatory eye condition characterized by the involvement of the immune response.This includes various types disease such as autoimmune uveitis,thyroidassociated eye disease,and primary Sjögren's syndrome.In recent years,breakthroughs have been achieved in inducing transplant tolerance,understanding tumor immune evasion,and preventing autoimmune diseases using immune checkpoint molecules.Negative immune checkpoints effectively control disease progression by inhibiting T cell proliferation,reducing inflammatory cytokine levels,and ultimately regulating autoimmune balance.Therefore,the negative immune checkpoint molecules are expected to be used as a new therapeutic target in the future,and the combination therapy through the combination of negative immune checkpoint drugs is expected to become an important direction to improve the efficacy of the treatment of autoimmune diseases.

关 键 词：自身免疫性眼病 免疫检查点分子 T细胞 综述 

分 类 号：R77[医药卫生—眼科]